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Abstract  
 
La estenosis aórtica (EA) es una de las enfermedades valvulares más comunes y una de 
las pocas afecciones cardíacas que afecta a hombres y mujeres en casi el mismo 
porcentaje. Es una condición para la cual no se ha establecido un tratamiento 
farmacológico, y el único tratamiento posible es el reemplazo valvular. Durante 
décadas, el reemplazo quirúrgico de la válvula aórtica (SAVR) fue el único tratamiento 
disponible para esta afección, pero la introducción del procedimiento de implantación 
de la válvula aórtica transcatéter (TAVI) ha cambiado la cardiología intervencionista y 
el procedimiento TAVI se ha establecido como el procedimiento de referencia para 
pacientes de alto riesgo, que a menudo se les niega la cirugía SAVR porque se 
consideran inoperables. 
Este trabajo se centra en las diferencias de sexo, los diversos factores biológicos en 
hombres y mujeres, que conducen a un desarrollo diferente en la estenosis aórtica 
fisiopatológica, con cada sexo presentando características específicas y la posible 
influencia de estas diferencias de sexo tanto en la presentación clínica como en la 
clínica. Resultados post-procedimiento después de TAVI y SAVR. 
Estas diferencias de sexo conducen a una remodelación diferente en respuesta a la 
sobrecarga de presión crónica causada por AS: las mujeres desarrollan un ventrículo 
izquierdo (LV) concéntricamente hipertrofiado de cavidad pequeña, mientras que los 
hombres desarrollan hipertrofia excéntrica. Los corazones masculinos con estenosis 
aórtica parecen tener más fibrosis que sus comparadores femeninos. Estas diferencias 
parecían estar relacionadas con la señalización del receptor de estrógenos, pero también 
intervienen otros factores. 
Este trabajo recopiló y analizó estudios que se centraron en el resultado en ambos sexos 
de SAVR, de TAVI y de los dos procedimientos en comparación con hombres y 
mujeres. 
El sexo femenino resultó ser un posible factor adverso después del procedimiento 
SAVR, con tasas de mortalidad más altas. Por el contrario, el sexo femenino parece 
conferir una ventaja de supervivencia después de TAVR, específicamente en las tasas 
de supervivencia a largo plazo (supervivencia de 1 año o más), esta ventaja no se 
registra a los 30 días después del procedimiento, donde las mujeres tienden a sufrir 
mayores Tasas de complicaciones. 
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Abstract 
 
Aortic stenosis (AS) is one of the most common valvular disease and one of the few 
cardiac conditions that affects men and women in approximately the same percentage. It 
is a condition for which no pharmacological cure has been established, and the only 
treatment possible is valve replacement. For decades Surgical Aortic Valve 
Replacement (SAVR) was the only available treatment for this condition, but the 
introduction of the Transcatheter Aortic Valve Implantation (TAVI) procedure has 
changed interventional cardiology and TAVI procedure has established itself as the 
benchmark procedure for high risk patients that are often denied SAVR surgery because 
deemed as “inoperable”. 
This works focuses on the sex-differences, the diverse biological factors in men and 
women that lead to a different development in the pathophysiology aortic stenosis, with 
each sex presenting specific characteristics and the possible influence of these sex-
differences in both clinical presentation and  post-procedural outcomes after TAVI and 
SAVR.  
These sex-differences lead to a different remodelling in response to the chronic pressure 
overload cause by AS: women develop a concentrically hypertrophied, small cavity left 
ventricle (LV), while men develop eccentric hypertrophy. Male hearts with aortic 
stenosis present a higher degree of fibrosis than female’s hearts. These differences 
appeared to be related with the estrogen receptor signalling, but other factors are also 
involved. 
This work collected and analyses studies that focused on the outcome in both sexes of 
SAVR, of TAVI and of the two procedures when compared in men and women. 
Female sex resulted being a possible adverse factor following SAVR procedure, with 
higher mortality rates. Conversely, female sex appears to confer a survival advantage 
following TAVR, specifically in the long-term survival rates (1-year survival or longer), 
this advantage not being registered at 30-day post-procedure, where women tend to 
suffer from higher rates of complications. 
  
 
Key-words: TAVI, SAVR, sex-difference, clinical trial, survival advanatge 
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Introduction 
 
Background 
Ever since the introduction of the TAVI interventional cardiology for the treatment of 
aortic stenosis has changed immensely . It has rapidly become one of the most common 
procedures for AS, representing the only viable option in high-risk or “inoperable” 
patients. Various studies have proven the superiority or non-inferiority of TAVR 
procedure when compared to SAVR in high-risk patients. 
AS is one of the few cardiovascular diseases that affects men and women at 
approximately the same rate. TAVI is commonly performed in women and, while 
female sex is usually identified as a risk factor in cardiac surgery, an emerging trend 
from various studies seems to show otherwise in the case of TAVI.  
 
Various studies have focused on the differences in outcome between female and male 
patients and registered a distinct impact of sex in TAVR outcomes. 
It is important to emphasise the relative novelty of this procedure which reflect on the 
information available. Due to its only recent introduction, long-term data on the 
outcome of TAVI is growing but still scarce, especially when compared to SAVR, an 
established procedure since the 1960’s.  
 
In addition to this most of the studies that focus on the possible sex-related differences 
in the outcome of the two procedures are retrospective, and consistent of an analysis of 
other trials where the primary endpoint were different to the comparison of outcome in 
men and women. 
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Sex and gender differences in cardiovascular diseases 
 
Biological variances among women and men are called sex differences. Sex differences 
in the cardiovascular system are as a result of differences in gene expression from the 
sex chromosomes, which may be further modified by sex differences in hormones, 
resulting in sex-unique gene expression and function. These differences result in 
variations in prevalence and presentation of cardiovascular conditions, including those 
associated with autonomic regulation, hypertension, DM, and vascular and cardiac 
remodelling. In contrast, gender differences are unique to the human and arise from 
sociocultural practices (behaviours, environment, lifestyle, nutrition). (19) 
 
It is essential to define when gender differences become gender disparities. Disparity is 
the lack of equality or the presence of inequity. The World Health Organization (WHO) 
has defined health inequity as “differences in health, which are not only unnecessary 
and avoidable but, in addition, are considered unfair and unjust”. Furthermore, the 
WHO defines equity in healthcare as “equal access to available care for equal need, 
equal utilization for equal need, and equal quality of care for all”. (46) 
 
To address gender disparities in the use of advanced therapies in cardiovascular 
medicine, it is imperative to reflect on federal laws that affect women’s health research. 
In 1977, the US Food and Drug Administration (FDA) issued a guideline, “General 
Considerations for the Clinical Evaluation of Drugs” restricting women of childbearing 
potential from participating in phase 1 and early phase 2 clinical studies until 
reproductive toxicity studies have been conducted in animals and some evidence of 
human effectiveness has become available. 
 
In 1985 the Public Health Service Task Force on Women’s Health Issues concluded that 
“the historical lack of research focus on women’s health concerns has compromised the 
quality of health information available to women as well as the health care they 
receive”. (41)To follow, the National Institutes of Health established the Office of 
Research on Women’s Health, and the US Department of Health and Human Services 
(HHS) established the Office on Women’s Health (OWH) to promote the inclusion of 
women in clinical research.   
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In recent years more studies have focused on researching the impact of sex and gender 
disparities in various diseases, with some great interest shown for cardiovascular 
diseases. These new studies are part of a relatively recent change in health research, 
where more attention is focused on women and the impact of cardiovascular diseases in 
the female sex. 
 
 Although cardiovascular disease has been responsible for more deaths in women than 
in men each year since 1985 women have been widely underrepresented in clinical trials 
which has reflected not only on the information of the impact of sex on different 
cardiovascular disease but has also led to a general underestimation of the impact of 
these diseases just as much in patients as in specialists.  As reported in a recent 
nationwide survey from the Women's Heart Alliance showed that almost half of women 
were unaware that CVD is the most frequent cause of death among women; 
interestingly, only 39% of primary care physicians considered CVD as a top concern, 
after weight and breast health. (19) 
  
It is clear that women have been underrepresented  and there is no doubt  that self-
awareness in women and the identification of their cardiovascular risk factors deserve 
more attention, which may lead to improved prevention of cardiovascular events and 
implementation of adequate treatment strategies. 
Furthermore, women are usually under-represented in randomized coronary clinical 
trials, accounting for approximately 25% of the patients. (4) 
 
One recent exception to this is represented by the studies regarding aortic stenosis and 
its treatment. 
In fact various studies have focused on studying the sex related differences in all of the 
various aspects of aortic stenosis from its pathophysiology to the outcome of the two 
possible treatments: transcatheter or surgical aortic valve replacement. 
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Aortic stenosis 
Aortic stenosis is the commonest form of valvular abnormality in the developed world 
and accounts for >40% of patients with native valvular disease with an approximately 
equal prevalence in males and females.(36).  
This condition is caused by the narrowing of the aortic valve orifice that leads to an 
obstruction of the left ventricular outflow and carries a poor prognosis if left untreated. 
Increased chamber filling pressures and reduced cardiac output lead to dyspnoea, which 
is one of the main symptom of Aortic Stenosis. Angina is also common in severe cases 
of stenosis and it may occur because of increased LV mass, poor coronary filling and 
reduced coronary flow reserve. Exertional pre-syncope and syncope also occur, 
probably owing to the fixed cardiac output at times of increased demand and 
vasodilatation or to arrhythmia. Unsurprisingly, the risk of sudden cardiac death 
increases with the severity of disease. (Clayton, Morgan-Hughes, & Roobottom, 2014) 
Aortic Stenosis in a population aged over 70 years is usually due to age-related 
calcification, but in younger patients, bicuspid valve is the primary cause. (39) The 
disease seems to be mediated by an inflammatory process, similar to that of 
atherosclerosis, calcific deposition may occur at the final stage in the healing process, 
akin to coronary atheroma. Progressive deposition and valvular thickening results in the 
obstruction of the LV outflow tract. Initially, the LV hypertrophies in an attempt to 
overcome this, but, overtime, the myocardium becomes less compliant with a rise in LV 
end-diastolic pressure and impairment of relaxation (diastolic dysfunction).(11) 
 
The population at risk rises in proportion to the improvement in life expectancy and a 
rapidly aging society, and it is also likely that this prevalence will progressively 
increase even further. Consequently, AS is now a major societal and economic burden 
that is likely to be substantiated in a near future and thus an urgent priority to 
understand the pathobiological processes leading to AS at the most fundamental level to 
improve preventive and therapeutic strategies. (5) 
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Pathophysiological Mechanisms of Aortic Stenosis  
Calcific aortic valve disease  encompasses  a wide  spectrum that begins with mild 
fibro-calcific leaflet changes, called aortic sclerosis, and progresses to more severe 
calcification with the end stage causing significant obstruction to ejection of the left 
ventricle, known as aortic stenosis (AS). 
From a clinically point of view, AS is characterized by a long unremarkable period 
(decades) and once symptoms develop, there is a poor prognosis and currently no 
medical therapies to prevent and/or promote the regression of the disease, whose natural 
history requires surgical valve replacement even in old, high-risk patients. (5) 
Until recent years the explanation for degenerative AS was a “mechanical” and passive 
condition caused by old age where a “wear and tear” effect leads to the calcium 
depositions within the valve. In recent years this idea has been challenged by various 
studies that suggest an active disease process, similar to that of atherosclerotic diseases, 
with multiple phenomena at the tissue level with anatomical, clinical and genetic factors 
possibly involve. 
Both calcific disease of the aortic valve and atherosclerosis are characterized by lipid 
infiltration, inflammation, neoangiogenesis, calcification and endothelial dysfunction. 
Furthermore, these two diseases often coexist.(47) 
Although aortic valve degeneration disease can be considered “atherosclerosis-like” 
there are some important differences between these diseases. Vascular atherosclerosis is 
an unstable process where plaque rupture is the major complication that leads to 
clinically relevant events. Conversely, in the progression of aortic valve degeneration a 
progressive calcification takes place, even with lamellar bone formation that leads to the 
immobility of the valve.  
As stated by Caritá et al. “atherosclerotic progression often leads to destabilization, 
while in aortic stenosis the permanent massive calcification of the aortic valve 
represents the advanced stage of the disease.” In conclusion, it is possible that vascular 
atherosclerosis and aortic stenosis share a similar pathophysiology background in the 
initial stages of the disease but are then followed by different mechanism of “evolution” 
at tissue level.  
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Specifically, it seems like an inflammatory process is involved in the initiation of aortic 
stenosis but isn´t the driving force of the evolution of the disease. Some of factors that 
are involved with the evolution and the progress of the disease are: calcification 
mediators that interact with the inflammatory cells, mechanical stress and genetic 
factors. 
The main response to the onset of AS is cardiac remodelling, defined by Cohn et al. as: 
‘‘genome expression, molecular, cellular, and interstitial changes that are manifested 
clinically as changes in size, shape, and function of the heart after injury’’(12). This 
remodelling results in LV hypertrophy (LVH) that is almost ubiquitous in severe AS, as 
a myocardial response to chronic elevation of afterload. Increased LV mass is 
associated with adverse events.(9) As stated by Dobson et al.: “ initially the LV adapts 
to the increase in wall stress by increasing myocyte size, allowing maintenance of 
ejection fraction but eventually progressive LV dysfunction occurs, initially affecting 
diastolic and then systolic function due to myocyte degeneration (a combination of 
apoptosis and oncosis)”(Fig. 1). 
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Fig.1 (A) Normal left ventricle (LV) mass and myocyte architecture. B) With progressive exposure to 
pressure overload and shear stress, the LV mass increases and myocytes become hypertrophied and an 
increase in sarcomeres leads to an increase in cell width. (C) Eventually LV systolic dysfunction 
develops due to a combination of sub endocardial ischaemia (due to reduced coronary flow reserve) 
and an inability of the myocyte to normalize wall stress by hypertrophic response alone. ((15) 
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The result of this left ventricular hypertrophy can result in three different patterns: 
concentric, eccentric, or asymmetric. (Fig.2) 
   
 
 
 
Fig 2. Potential mechanisms for differing patterns of LV remodelling between sexes in aortic 
1stenosis.(15) 
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Left ventricular remodelling 
Women with AS demonstrate specific clinical, anatomic, and pathophysiological 
features in myocardial adaptation to AS both before and after valve replacement. 
One of the most thorough systematic studies regarding sex differences in the 
development and treatment of AS was conducted by Dobson et al. The study consisted 
of a systematic literature search for studies published between January 1, 1980, and 
May 31, 2014.  
As stated by Dobson et al.: “In the normal heart, there are macroscopic and 
physiological differences between sexes. Due to their smaller body size, women have 
smaller hearts and therefore a lower stroke volume than men. Women have higher LV 
torsion and circumferential shortening compared with males due to an inherent 
difference in cardiac shape and fibre orientation. Women have reduced sympathetic 
tone, as reflected by lower peripheral vascular resistance and increased parasympathetic 
tone in relation to men. Other differences include lower circulating levels of red blood 
cells (reflected in a lower haematocrit level), noradrenaline, and plasma albumin in 
females, alongside the obvious difference in hormonal profile.”(15) 
The response to aortic stenosis of the left ventricle to pressure overload goes from a 
compensated hypertrophy to overt heart failure. Women exhibit more concentric 
remodelling and subsequent concentric LV hypertrophy (LVH), with higher relative 
wall thickness and smaller end-diastolic diameter than seen in men, who are frequently 
are found to have a higher prevalence of eccentric hypertrophy in this setting. (6)  
Sex hormones and estrogen receptors and their signalling pathways, which can remain 
active even after menopause, may play a role in sex-specific LV remodelling, because 
estrogen binding can modulate growth-factor signalling, modulating myocyte necrosis 
and apoptosis in animal models.(15) 
The role of estrogen receptors in the development of the left ventricle hypertrophy was 
the focus of the study of Mahmoodzadeh, et al, supported by the work of Levin. In their 
study they explains that: “estrogen receptors (ERs) a and b can be found in both male 
and female myocardium and are felt to be implicated in the development of myocardial 
hypertrophy,(27)with estrogen binding having genomic effects on gene transcription 
and non-genomic effects such as protein kinase activation, initiation of intracellular 
signalling cascades, and modulation of growth factor signalling.(25)” 
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Another factor that differentiates the two sexes in this pathology is that the 
physiological and biochemical basis for myocyte function is different according to sex. 
Males with severe AS are thought to have increased collagen 1, collagen 3, and 
metalloproteinase even in the context of normal LVEF.(18)  In one of his studies, 
Petrov et al. evaluated biopsies from 10 human hearts with severe AS and compared 
them with normal controls. Men with AS had higher levels of collagen 1, collagen 3, 
and matrix metalloproteinase-2 gene expression compared with females with AS or 
controls, and this correlated with the degree of hypertrophy and changes in LV 
geometry (37).  
 
This suggests a different regulation of matrix synthesis and make up of extracellular 
volume according to sex.  In order to further explore this altered extracellular volume in 
men, the group lead a comparative study of rat cardiac fibroblasts treated with 17b-
estradiol and found a down-regulation of collagen 1, collagen 3, and mRNA levels in 
female rat fibroblasts but increased expression in male rat cells. This is consistent with 
the finding that in aging hearts without AS, there appears to be more fibrosis in male 
hearts.(33) Women with AS may therefore develop a different form of remodelled 
hypertrophy distinguished by less fibrosis in the heart. 
 
 Another factor that differentiates the two sexes during the left ventricular remodelling 
is interstitial fibrosis. Findings from Villari et al.’s work showed that interstitial fibrosis 
was more marked in male hearts with AS when compared with female hearts. (45) 
 The study also noted that total collagen volume and systolic function ere not correlated, 
although there was an inverse relationship between ‘‘cross-hatching’’ (orthogonal 
collagen fibre meshwork) and LV systolic function.  High levels of crosshatching 
resulted in stiffer hearts. The conclusions to this study were that an increase in the 
extracellular volume does not relate to reduced ejection fraction but once abnormal 
collagen architecture has developed, there is deterioration in systolic and diastolic LV 
function. (15) 
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As a result of sex-specific myocardial adaptations to AS, women undergoing TAVR 
have a smaller LV cavity and higher LV ejection fraction (LVEF).(8)  In general, 
women are smaller than men and have been found to have a LV outflow tract (LVOT) 
that is narrower with a smaller aortic annulus,(30) smaller calculated aortic valve area 
(AVA),(23) lower LV end-diastolic volume, higher transvalvular gradient,(32) and 
lower stroke volume than men.. All of these anatomic features should be carefully 
considered during diagnostic imaging, because errors in measurements of LVOT and 
failure to consider smaller body surface area and stroke volume index are common 
mistakes in the evaluation of AVA and subsequent determination of AS severity. 
 Concentric hypertrophy and a smaller LV cavity increase the risk for women to develop  
paradoxical low-flow, low-gradient AS, defined as an AVA  0.6 cm/m2, a mean aortic 
gradient < 40 mm Hg, and a low indexed stroke volume (< 35 mL/m2) in the setting of 
preserved LVEF ≥ 50%.(31)  
The majority of patients showing the previously mentioned type of AS are, in fact, 
women. According to Hachich et al. patients diagnosed with low-flow, low-gradient AS 
have poorer 3-year survival. (21) 
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Fig.3: Sex-differences in LV remodelling. (35) 
 20   
 
 Table 1: Sex differences in aortic stenosis and results of TAVR. (35) 
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Reverse Remodelling After SAVI and TAVR 
The effect of sex on the outcome of the two procedures is very difficult to evaluate. In 
the case of SAVI one of the first systematic reviews of outcomes of SAVR in patients 
with AS, by Sharma et al., found that sex did not impact on LV mass regression and 
change in ejection factor.(42) Of course it is to be noted that the study by Sharma et al. 
consisted of largely historic studies which are now out-dated. Dobson et al. analysed 
some larger and more recent studies but results are mixed and are extracted from a 
heterogeneous group of patients. They concluded that: “in theory, females’ smaller body 
size require smaller aortic valves which are associated with a higher postoperative 
transvalvular gradient and subsequently less LV mass regression” (15) 
In the case of TAVI, evidence about the effect of sex on remodelling after procedure is 
scarce. This is due to the fact that it is a relatively new technique, so there is fewer long-
term data and the findings are discording. In general female patients who have 
undergone TAVR show beneficial LV remodelling after correction of AS. As stated 
previously women undergoing AVR have less fibrosis than men.  
 
The lower incidence of fibrosis, which can lead to potentially irreversible non 
concentric LV remodelling, likely supports regression of concentric LVH observed in 
women after TAVR. A study of 690 patients from the PARTNER trial, in a study 
conducted by Lindman et al., showed that, a greater LV mass index regression at 30-day 
and 1-year follow-up was associated with female sex (P ¼ 0.009) and with a lower 
overall rate of hospitalizations for heart failure (P ¼ 0.002) (18).  
 
This decrease in hospitalizations is possibly linked to improvement in both diastolic and 
systolic function after TAVR.  Another study, by Stangl et al., discovered that women 
had improved short-term LV recovery and obtained significant improvement of LVEF 
after TAVR, whereas men did not (44).  
 
Another factor that may be involved in the different remodelling between sexes after 
TAVR that has been examined is the degree of systemic inflammation. Stang et al. 
reported that “the inflammatory marker C-reactive protein, but not interleukin 6, was 
found to be completely normalized in women 3 months after TAVR but not in 
men.”(44). Further data are needed to confirm whether sex-specific inflammatory 
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pathways are implicated in the observed remodelling differences between women and 
men. 
A study by Clavel et al. compared the effect of both procedures with respect to post-
operative recovery of LVEF. In the study, TAVI patients had better recovery of LVEF 
compared with SAVR patients (ΔLVEF, 14±15% versus 7±11%; P=0.005). At the 1-
year follow-up, 58% of TAVI patients had a normalization of LVEF (>50%) as opposed 
to 20% in the SAVR group. On multivariable analysis, female gender (P=0.004), lower 
LVEF at baseline (P=0.005), absence of atrial fibrillation (P=0.01), TAVI (P=0.007), 
and larger increase in aortic valve area after the procedure (P=0.01) were independently 
associated with better recovery of LVEF. (10) 
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History of SAVR 
 
Since the first aortic valve replacement in 1960, this procedure has been the only life-
saving and available option for millions of patients. Surgical aortic valve replacement 
(SAVR) represented the only possible treatment for severe aortic valve stenosis. The 
recent introduction of transcatheter aortic valve replacement has created an alternative 
to this open heart surgery procedure and an opportunity to the portion of patients 
deemed inoperable for SAVR. 
 
SAVR is a complicated surgical procedure that requires the use of the heart lung 
machine to stop the heart and to allow access to the aortic valve within the heart. The 
traditional approach consist in exposing the heart for bypass it accesses the aortic valve 
via median sternotomy. This route of access ensures excellent access to all cardiac 
structures but requires complete division of the sternum and sternal spreading. Surgeons 
therefore decided to search for less invasive ways of performing SAVR in the hope of 
achieving easier recovery and possibly improved results for patients. (38)  
 
The two minimal approaches most widely used for SAVR are: 
 
 The right mini thoracotomy approach, introduced by Benetti in 1997 (3) 
 The mini sternotomy approach by Gundry in 1998. (20) 
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History of TAVI 
The history of the development of a permanent “stent valve”, catheter-mounted, 
balloon-deployable valve prosthesis dates back as far as the 1960s and the 1970s when 
the first preliminary animal studies and devices were developed. Further studies ensued 
but the first TAVI was performed only in 2002. (13)  
In the last 15 years, interventional cardiology has been revolutionised by transcatheter 
aortic valve implantation (TAVI). The initial promise borne out of results from seminal 
clinical trials has been substantiated by data from numerous real-world registries, and 
TAVI has become the established treatment for severe, symptomatic aortic stenosis 
(AS) in patients unable to undergo surgical aortic valve replacement (24) due to 
prohibitive risk. The success of  TAVI  in these patients has led to an expansion of its 
use, and in the near future it could potentially be used in a wider range of patients such 
as those with lower surgical risk or with bicuspid aortic valves (BAV). (1) 
 
TAV is  now an established, valid treatment for patients suffering from severe aortic 
stenosis. Its results have proven this procedure to be superior to medical treatment for 
inoperable patients and also a valid alternative to surgery in high-risk patients.  
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TAVI procedure 
Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of 
patients with severe, symptomatic aortic stenosis, becoming a first-line therapeutic 
option among patients at increased surgical risk. (31) 
A transcatheter aortic valve (TAV) is designed to be compressed into a small diameter 
catheter, remotely placed within a patient’s diseased aortic valve under fluoroscopic 
guidance to take over the function of the native valve.(14)  
Most procedures are performed using a retrograde approach. Femoral or alternative 
arterial, access is achieved using a standard Seldinger technique, with retrograde 
puncture and a vascular sheath. This is most commonly achieved percutaneously, 
although cut-down procedures may be useful, particularly where the target vessel is 
calcified or stenosed. Venous access is also obtained for the purposes of a right 
ventricular temporary pacing wire. Once access is achieved, the patient is 
anticoagulated with unfractionated heparin or bivalirudin. The aortic valve is crossed 
using a guide wire, followed by a diagnostic coronary catheter to undertake transducer 
assessment of the aortic valve gradient. (11) 
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TAVI  Devices
 
Fig. 4: Transcatheter aortic valves FDA-approved for clinical use in the U.S.(14) 
There are two main types of Transcatheter valves: TAVs (e.g., Edwards SAPIEN 
family)  
 Balloon-expandable TAVs (e.g., Edwards SAPIEN family) 
 Self-expandable owing to their shape-memory nitinol stents (e.g. Medtronic’s 
CoreValve)  
In both cases, the TAVs are deployed within a calcified native valve that is forced 
permanently open and becomes the surface against which the stent is held in place by 
friction. The design features, which most distinguish TAVs from their surgical 
counterparts -except for suture-less SAVRs- are the lack of a sewing cuff and the 
presence of a collapsible stent frame that houses the valve leaflets. (14) 
The choice of valve prosthesis in an individual patient is based on consideration of 
several factors, including valve durability, expected hemodynamic for a specific valve 
type and size, surgical or interventional risk and  patient values and preferences. 
Specifically, the trade-off between the potential need for intervention for bio-prosthetic 
structural valve deterioration and the risk associated with long-term anticoagulation 
should be discussed in detail with the patient. Several other factors must be taken into 
consideration in a decision about the type of valve prosthesis, including other 
comorbidities. Age is important because the incidence of structural deterioration of a 
bio-prosthesis is greater in younger patients, but the risk of bleeding from 
anticoagulation is higher in older patients  
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A mechanical valve might be a prudent choice for patients for whom a second surgical 
procedure would be high risk (i.e., those with prior radiation therapy or a porcelain 
aorta).(31) In patients with shortened longevity and/or multiple comorbidities, a bio-
prosthesis would be most appropriate.  
In women who desire subsequent pregnancy, the issue of anticoagulation during 
pregnancy is an additional consideration. (31) 
Most devices use a catheter-mounted valve constructed of a metal alloy frame, with 
leaflets cut from animal pericardium. Manufacturers must balance the security and 
robustness of the device with its insertion technique and cross-sectional profile when 
mounted on an introducer. For example, equine or bovine pericardium is generally 
considered to be harder wearing than porcine material but is bulkier, requiring larger 
sheaths for vascular access. Modern devices also attempt to limit paravalvular leak and 
to preserve the ability to reposition the device in the event of inaccurate deployment. 
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Objectives 
The aim of this study is to concisely and thoroughly examine the existing literature on 
the topic and compare the results from various previous studies that analyse potential 
sex-related differences in outcome in both procedures, TAVI and SAVR. 
 The study also aims as to give a complete vision of the possible sex-related factors that 
determine these different presentations of the condition and influence the outcome of 
both procedures. 
Ultimately, the study analyses a total of 14 studies that focus on the sex-related 
differences present in  the outcome of both procedure in order to establish if a female  
sex advantage exists for the TAVI procedure and the possible existence of a 
disadvantage in SAVR for women. 
 
 
 
 
Methods 
Information for this work was retrieved by doing a systematic  search of PubMed, Web 
of Science, Scopus from inception until 2019 without language restriction, using key 
words “sex,” “gender,” “gender differences,” “comparison,” “men,” “women,” “male,” 
“female,” “transcatheter aortic valve replacement,” “transcatheter aortic valve 
implantation,” “surgical aortic valve replacement,” “surgical aortic valve implantation” 
both separately and in combination.  
The research included bibliographies of retrieved articles. To be included studies had to 
analyse clinical outcome in patients with aortic stenosis who underwent TAVR or 
SAVR, or a comparison of the outcome of the two procedures. No language restrictions 
were applied. 
The inclusion criteria applied for the article selection were the following: 1) studies of 
patients with severe aortic valve stenosis undergoing SAVR or TAVI; 2) single-group 
cohort or a controlled comparison between TAVI and SAVR;3) available data on at 
least short term (30 days or in hospital or 1-year all-cause mortality) 
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Sex-Related Differences in Outcomes after Surgical Aortic Valve Replacement  
Severe aortic stenosis that requires surgery is increasing as the elderly population grows 
with more women than men affected due to their longer life-span. Surgical aortic valve 
replacement (SAVR) reduces mortality, provides symptom relief and increased quality 
of life at subsequent follow-up. (29) 
Surgical aortic valve replacement (SAVR) has been available since the 1960s and was 
for a long time the only available treatment for patients with aortic stenosis. Advanced 
age and various comorbidities represent important risk factors for operative risk which 
represents a problem considering that AS usually appears at an advanced age. 
Furthermore a great limitation of SAVR is represented by that group of patients deemed 
as “inoperable” such as those with porcelain aorta or a hostile mediastinum from 
previous radiotherapy in whom surgery is not technically possible. These factors left a 
substantial portion of patients untreated despite their very poor diagnosis.  
 
Surgery in women is usually more technically demanding due to smaller annuli size, 
increased need for aortic enlargement, and complications related to cardiopulmonary 
bypass. Also, women tend to be older and in a more advanced stage of the disease with 
greater frailty at the time of surgical referral.(15). 
 
The effect of sex on the outcome of SAVR is difficult to accurately evaluate and various 
studies have focused on discovering and study the extent of the influence of sex 
differences in the outcome of this procedure, in an effort to provide the best possible 
treatment for patients. 
The study conducted by Chaker et al. hypothesized that female patients have worse 
outcomes following AVR compared with male patients. The study proposed that if the 
hypothesis turned out to be true then perhaps women should be offered TAVR over 
surgical AVR at a lower threshold compared with men, given the mounting evidence of 
better outcomes of TAVR in women versus men.(7) 
 
Chaker’s study is a retrospective analysis of the patient-relevant information between 
January 2003 and December 2014 from the Nationwide Inpatient Sample (NIS). 
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In total, 166 809 patients (63% male and 37% female) who underwent AVR between 
2003 and 2014 were identified, and among these, 85 975 (51.5%) had isolated AVR. 
The majority of these patients (60.8%) were men.  
The study outlined the different baseline conditions between the two sexes. Women 
were older and had more non atherosclerotic comorbid conditions including 
hypertension, diabetes mellitus, obstructive pulmonary disease, atrial ﬁbrillation/ﬂutter, 
and anaemia but fewer incidences of coronary and peripheral arterial disease and prior 
sternotomies. 
 The major findings of the current investigations are as follows. Firstly, men undergo 
SAVR for AS more than women. From Table 2 it is noticeable that the disparity is more 
pronounced in recent years. The growing divergence between men and women is linked 
to the arrival of TAVR as a new procedure. Since TAVR became commercially 
available in the United States in 2011, women have been referred more often to TAVR 
versus AVR compared with men this may explain the later divergence of utilization 
trends of AVR between men and women. (7) 
 
Table. 2: Percentage of TAVR and SAVR among Males and Females since 
commercial approval of TAVR. ((7) 
Second, women who underwent AVR in the United States between 2003 and 2014 were 
older and had distinctive risk profiles and demographics compared with men. Third, 
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women had higher unadjusted and adjusted in-hospital mortality following AVR than 
men, and this was consistent over time. Fourth, after risk adjustment, women had more 
vascular complications and blood transfusions than men and were more likely to be 
discharged to a skilled nursing facility, nursing home, or intermediate care centre.(7)  
A lot of the results of the Chaker et al. study were in accordance with another study, by 
Lopez de Andrés et al. that also consisted of a retrospective analysis of data from 2001 
to 2015 with the aim of creating a simple and direct comparison of baseline covariates 
between women and men. 
The data for this study was obtained from the Spanish National Hospital Discharge 
Database and the authors identified a total of 86 578 hospitalizations of patients aged 18 
years or more who underwent SAVR in Spain (2001–15). Women accounted for 40% of 
the total (n = 34 647).  
This study also showed different baseline characteristics between the two sexes, in 
accordance with Chaker’s study, the results showed that women, compared with men, 
were older (72.19 ±9.59 vs. 67.89 ± 11.54) and had higher rates of T2DM, congestive 
heart failure, atrial fibrillation, and pulmonary hypertension. In contrast, COPD, 
peripheral vascular disease, renal disease, cerebrovascular disease, and coronary artery 
disease were more prevalent in men. 
As seen in Chaker’s study, this study showed a decreasing trend for women to undergo 
SAVR procedure, not shown in men. This difference has been linked to a disparity in 
referral for testing, since women are less likely to receive specialists visits, diagnostic 
testing and SAVR.(7) 
 In fact the study showed that in the past 15 years there has been an increase in the 
number of heart valve surgeries in Spain. The studies tried to find a motivation for this 
decrease of SAVR procedure in women. Chaker et al. concluded that women diagnosed 
with aortic stenosis had unfavourable preoperative baseline characteristics compared 
with men at the time of presentation and thus were less likely to be referred to surgical 
treatment. Another explanation is that men underwent SAVR for lower degrees of aortic 
valve disease at the time of coronary bypass, contributing to the larger number of men 
undergoing SAVR overall. Finally, recent studies have found that after the introduction 
of TAVI a slight declined of SAVR was observed over time17–19 and women have 
been referred more often to TAVI versus SAVR compared with men,20,21 this may 
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also explain part of the later divergence of utilization trends of SAVR between men and 
women. 
Lopez et al analysed the Spanish National Hospital Discharge Database with the aim of 
: 1) examine the trends in the incidence, characteristics and in-hospital outcomes of 
SAVR among women and men from 2001 to 2015; 2) compare in-hospital outcomes for 
mechanical and bio-prosthetic SAVR in women and men using propensity score (PS) 
matching (PSM); and 3) identify factors associated with in-hospital mortality (IHM) 
among women and men according to implanted valve type of SAVR (26) 
The study concluded that overall IHM after mechanical SAVR was significantly higher 
in women than in matched men (8.94 vs. 6.79%) (P < 0.001). After stratification by ER 
admission, Lopez et al found that female gender was associated to significant higher 
IHM among those who received mechanical SAVR with no ER admission (OR 1.51; 
95%CI 1.34–1.70) and those admitted through the ER (OR 1.21; 95%CI 1.04– 1.41). 
For bio-prosthetic SAVR, females had higher risk of dying only if not admitted through 
the ER (OR 1.42; 95%CI 1.25–1.61). 
 
The final conclusion of this nation-wide analysis was that overall IHM of all type of 
SAVR, mechanical or bio prosthetic was higher in women than in men. This finding is 
in accordance with the results from Chaker et al which also found that IHM was 
significantly higher in women than men (analysis of the National Inpatient Sample data 
of 166 809 patients who underwent SAVR between 2003 and 2014) (7). This nation-
wide analysis of gender-specific outcomes after SAVR showed that, after PSM women 
have significantly higher than men. 
Another retrospective analysis, by Duncan et al., found a less significant difference in 
outcome between the two sexes. Duncan et al. retrospectively analysed 2212 patients 
undergoing isolated SAVR over a 9-year period, and although unadjusted in-hospital 
mortality appeared to be higher in females (3.5% females vs. 1.6% males) propensity 
matching did not find a significant difference in mortality between sexes. These results 
suggest that there is no greater than a 2.5-fold increase in risk for females compared 
with males undergoing AVR. Female gender, however, may impart increased risk for 
cardiac morbidity after AVR.(16)  
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A recent study from Elhmidi et al. consisted on a retrospective analysis of all patients 
undergoing isolated SAVR from 2000 to 2011 in the Clinic for Cardiovascular Surgery, 
German Heart Centre in Munich. A total of 2197 patients were included, 1290 (58.7%) 
male patients and 907 (41.3%) female patients. The same baseline characteristics as 
seen in the previous studies were found in both groups, while the results were slightly 
different. After adjustment for baseline characteristics, only female gender was an 
independent predictor for 30-day mortality (HR 2.2, 95% CI 0.98 to 5.2, p = 0.05) and 
age as independent predictor for late mortality (HR 1.07, 95% CI 1.03 to 1.1, p<0.001) 
(17). Elhmidi et al. concluded that: “Female patients were older and sicker and may 
therefore exhibit higher 30-day and late mortality than male patients. Female gender per 
se was a predictor for 30-day but not for late mortality.” (17) 
 
A great number of studies have been conducted with the aim of proving sex to be a 
prognostic factor and results have been discordant. Although, in general, females do 
appear to have an increased morbidity following SAVR; with  one recent study  from 
Onorati et al. of 6809 patients undergoing SAVR showing a higher rate of postoperative 
stroke in women compared with men (3% vs. 2.2%, p = 0.031). At least in theory, 
females’ smaller body size require smaller aortic valves which are associated with a 
higher postoperative transvalvular gradient and subsequently less LV mass 
regression.(9) 
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Sex-Relate Differences in the Outcome of TAVI Compared To SAVR 
Interventional cardiology has changed greatly since the introduction of transcatheter 
aortic valve implantation (TAVI), which has become the standard treatment for severe 
aortic stenosis in patients at high risk for surgical aortic valve replacement (24). (2) 
TAVI represents the only viable option the treatment for AS for a large percentage of 
patients, previously deemed as “inoperable”. Due to the fact that TAVR is a relatively 
new technique, few long-term data regarding sex differences are available and the 
findings are discordant. 
The PARTNER Trial represented one of the first and largest randomized trials that 
compared the two procedures. A sub-analysis of the PARTNER A trial, which 
randomized 699 high-risk patients (42,9% female), was conducted by Williams et al.  
The study showed, in accordance with other results, that women were older than men 
with less important comorbidities. Women also showed lower  procedural mortality 
with TAVR versus SAVR (6.8% vs. 13.1%; p ¼ 0.07 but a higher stroke rate. 
Procedural mortality was significantly lower in men undergoing TAVR compared with 
SAVR (6% vs. 12.1%, p = 0.03) with no difference between the two techniques in terms 
of stroke. 
 At 2 year follow up, all-cause mortality in the female TAVR group was significantly 
lower than the female SAVR group (hazard ratio [HR] 0.67), driven by a very 
significant reduction in women undergoing transfemoral TAVR, and no mortality 
benefit in those with a transapical access route. There was no survival advantage in men 
undergoing TAVR compared with SAVR at 2 years. (48) 
Another relevant study that compared the two procedures was the multicentre Italian 
Observational Multicentre Registry (34) that enrolled 2108 patients undergoing TAVR 
and SAVR across 101 heart centres, women represented 44% of the SAVR population 
The study focused on the differences in physiology, disease pathology, presentation and 
management that could play a role in of the sex-differences observed in clinical 
outcomes of valve surgery. 
Onorati et al. found that the lower body weight and serum albumin level of women, and 
parallel cardiac structures that are smaller than the corresponding of men, could result in 
more technically demanding procedure. Female sex was an independent predictor of 
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risk-adjusted 30- day mortality following SAVR compared with males (3.7% female vs. 
2.2% male, p = 0.043, odds ratio [OR] 2.34). Women were more likely than men to 
undergo blood transfusions (OR 1.47), possibly due to a lower level of haemoglobin 
preoperatively. (34) (15) 
An interesting study by Skelding et al. showed the different outcomes of the two 
surgeries but in an only female population, so that the baseline differences between  the 
two groups would not differ greatly.. The aim of this study was to compare the 
outcomes in  women after surgical aortic valve replacement (SAVR) versus 
transcatheter aortic valve replacement (TAVR) using a self-expanding prosthesis in 
patients with severe aortic stenosis who were at high risk for SAVR. 
 
In this study treatment was attempted in a total of 353 women (183 TAVR and 170 
SAVR). As stated before, baseline characteristics and predicted risk of the 2 groups 
were comparable, although the frequency of diabetes mellitus was lower in patients 
undergoing TAVR (33.3% vs. 45.3%; p [ 0.02). The results show that TAVR-treated 
patients experienced a statistically significant 1-year survival advantage compared with 
SAVR patients (12.7% vs. 21.8%; p [ 0.03). The composite all-cause mortality or major 
stroke rate also favoured TAVR (14.9% vs. 24.2%; p [ 0.04).  
Quality of life, for both the TAVR and SAVR groups increased significantly from 
baseline to 1 year. In conclusion, the study showed that  female TAVR patients had 
lower 1-year mortality and lower 1-year all-cause mortality or major stroke compared 
with women undergoing SAVR, with both cohorts experiencing improved quality of 
life. Further studies specifically in women are warranted to validate these findings. (43) 
 
One of the most recent and thorough meta-analysis on the topic is the work of Panoulas 
et al. It’s a meta-analysis of the gender subgroups of four randomised controlled trials 
that met the criteria, totalling 3758 patients, 1706 women and 2052 men. The aim of 
this study was to determine whether gender affects the survival comparison between 
TAVI and SAVR. For this they analysed 4 randomised clinical trials (Table 3) 
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Table 3:. Characteristics of randomised controlled trials and propensity matched 
studies included in the current meta-analysis.(36) 
 
The female  TAVI recipients had a significantly lower mortality than  female SAVR 
recipients, at 1 year (OR 0.68; 95%CI 0.50 to 0.94) and at 2 years (OR 0.74; 95%CI 
0.58 to 0.95). Amongst males there was no difference in mortality between TAVI and 
SAVR, at 1 year (OR 1.09; 95%CI 0.86 to 1.39) or 2 years (OR 1.05; 95%CI 0.85 to 
1.3). This analysis of the gender-specific results of 3758 patients randomised between 
TAVI and SAVR indicates that for the women, TAVI gives significantly better survival 
than SAVR. Not only do men not show this pattern, but also the difference between the 
genders is statistically significant. (Table 4) 
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Table 4: Forest plot showing 1-year survival in females and males treated with either 
TAVI or SAVR. (36) 
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Women´s Outcome with TAVI 
 
As stated beforehand, TAVI procedure has revolutionized the treatment for AS. The 
first PARTNER trial was published in 2010, and since then, there has been cumulative 
evidence including robust registry data that strongly suggests sex differences exist in the 
use of TAVR. Women who undergo TAVR are older and deemed to be frailer than male 
counterparts, though LVEF is generally higher and women less frequently have a 
history of coronary artery disease and prior coronary revascularization. (28) 
 
The first accurate description of sex-related differences in patients with severe AS 
undergoing TAVI was conducted by Hayashida et al. in 2012. It consisted of a 
prospective registry of 260 patients undergoing TAVR, 72 female patients, between 
October 2006 and December 2010. The women were of similar age to men but with less 
coronary disease and  higher LVEF. The study found “no significant sex differences 
with respect to the 30-day mortality rate” but a better midterm survival for women.(22) 
Male sex was also identified as a predictor of midterm mortality. 
 
Furthermore, as stated by Hayashida et al.: “women had an improved 1-year survival 
compared with males (76% vs. 65%); however, baseline characteristics between the two 
groups were not corrected for.”.  
In conclusion, the results of the study showed that 1-year survival rate was higher for 
women, 76% (95% confidence interval: 72% to 80%), than for men, 65% (95% 
confidence interval: 60% to 69%); and male sex (hazard ratio: 1.62, 95% confidence 
interval: 1.03 to 2.53, p  0.037) was identified as a predictor of midterm mortality by 
Cox regression analysis.(22) 
  
A larger study, published at the same time by Humphries et al, recorded a prospective 
database of 641 patients undergoing TAVR over a 6-year period.  Like in the other 
studies, women were more frail but with less comorbidity and a higher LVEF than men. 
This study registered an improved survival in women at 2 years (72.5% in women and 
61.7% in men, 95% CI 54.1%–68.3%). This mortality benefit was maintained even 
when demographic, clinical, and procedural factors were corrected for (HR 0.55). (23) 
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Given the results of the study, which were in accordance with the findings from  the 
PARTNER1A trial, Humphries et al suggested that “TAVR might be the preferred 
treatment option for elderly women with symptomatic severe aortic stenosis.”  
 
O’Connor et al. conducted one of the largest meta-analysis on the topic of women’s 
survival after TAVI procedure. The group’s aim was to evaluate the impact of sex on 
early and late mortality. In order to do so the team included five studies and their on-
going registry data, for a total of 11310 patients. Women constituted 48.6% of the 
cohort and had less comorbidity than men.  
 
Women had a  higher incidence major vascular complications (6.3% vs. 3.4%; p < 
0.001), major bleeding events (10.5% vs. 8.5%; p ¼ 0.003), and stroke (4.4% vs. 3.6%; 
p ¼ 0.029) but a lower rate of significant aortic incompetence (grade $2; 19.4% vs. 
24.5%; p < 0.001). There were no differences in procedural and 30-day mortality 
between women and men (2.6 % vs. 2.2% [p ¼ 0.24] and 6.5% vs. 6.5% [p ¼ 0.93], 
respectively), but female sex was independently associated with improved survival at 
median follow-up of 387 days (interquartile range: 192 to 730 days) from the index 
procedure (adjusted hazard ratio: 0.79; 95% confidence interval: 0.73 to 0.86; p ¼ 
0.001). (Table 5). (32) 
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Table 5: 30--day outcome vs. late outcome in male and female patients.(32) 
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Table 6:  Overall survival rates during follow-up period. (32) 
 
A more recent study on the topic, which enclosed roughly the same amount of 
participants as O’Connor’s, come from Chandrasekhar et al. The 2016 study analysed 
the data from the Society of Thoracic Surgeons/American College of Cardiology 
Transcatheter Valve Therapy Registry from 2011 to 2014, with the aim being to 
compare in-hospital and 1-year outcomes in female and male subject.  The data 
amounted to a total of 11,808 (49.9%) women and 11,844 (51.1%) men that underwent 
TAVR.  
In accordance to previous studies , compared with male patients, female patients were 
older, with a lower prevalence of coronary artery disease, atrial fibrillation, and diabetes 
but a higher rate of porcelain aorta, lower glomerular filtration rate.  The study showed 
that “ in-hospital vascular complications were higher in women (8.27% vs. 4.39%; 
adjusted hazard ratio [HR]: 1.70; 95% CI: 1.34 to 2.14; p < 0.001) and a trend toward 
higher bleeding (8.01% vs. 5.96%; adjusted HR: 1.19; 95% CI: 0.99 to 1.44; p ¼ 0.06) 
 42   
 
was observed; however, 1-year mortality was lower (21.3% vs. 24.5%; adjusted HR: 
0.73; 95% CI: 0.63 to 0.85; p < 0.001) in women than in men.” (8) 
Such an extensive registry allowed Chandrasekhar et al. to analyse different aspects of 
this comparison and one of their findings showed that female patients undergo non 
transfemoral TAVR more often and have a higher incidence of device-related coronary 
obstruction and conversion to open surgery than male patients (despite smaller TAVR 
device sizes, female patients achieved a more optimal valve cover index than male 
patients) (8). These differences are shown in Fig.2 
 
Fig 2 :Differences in TAVR Approaches Among Male and Female Patients. (8) 
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The study from Saad et al. is one of the most recent and most comprehensive reviews on 
the topic to date. The study analyses seventeen studies of which eight were TAVR 
registries, amounting to  a total of 23,303 women and 23,885 men available for the final 
analysis. Eight studies were conducted in North/South American centres, and 9 in 
European centres. All studies included patients deemed inoperable or at high-risk for 
SAVR, except for one,  the PARTNER 2 Sapien 3 study, which included an 
intermediate-risk cohort as well. 
In keeping with the previous studies, men and women differed in their baseline 
characteristics. As the study reports “Women were older compared with men (age 82.7  
1.2 years vs. 81.8 1.4 years; p ¼ 0.0001); however, men had more comorbidities at 
baseline including diabetes mellitus, hypertension, atrial fibrillation, coronary artery 
disease, peripheral arterial disease, history of MI, prior percutaneous coronary 
intervention or coronary artery bypass.” (40) 
The primary endpoints of this review were: 30 day survival and all-cause mortality. At 
30 days, women had more bleeding (p < 0.001), vascular complications (p < 0.001), and 
stroke/transient ischemic attack (p ¼ 0.02), without difference in all-cause (p ¼ 0.19) or 
cardiovascular mortality (p ¼ 0.91) compared with men.  
However, female sex was associated with lower all-cause mortality at 1 year (risk ratio: 
0.85; 95% confidence interval: 0.79 to 0.91; p < 0.001), and longest available follow-up 
(mean 3.28 1.04 years; risk ratio: 0.86; 95% confidence interval: 0.81 to 0.92; p < 
0.001), potentially caused by less moderate/severe aortic insufficiency (p ¼ 0.001), and 
lower cardiovascular mortality (p ¼ 0.009).  
This overall lower rate of mortality for females remained  unvaried in various secondary 
analyses.  The authors  noted  that risk of stroke, moderate/severe aortic insufficiency, 
and all-cause mortality seemed to vary based on the type of valve used; however, 
without significant subgroup interactions. (40) 
The study, a meta-analysis of 47,188 patients showed that women have a higher risk of 
early post-operative complications but an overall better long-term survival after TAVR, 
in comparison with men.  
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Table 6: Forest Plot of All-Cause Mortality in Women Versus Men at Short-, 
Intermediate-, and Long-Term Follow-Up After TAVI. (40) 
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Table 7: Forest Plot of Major Bleeding, Need for Transfusion, and Vascular Access 
Complications in Women Versus Men at 30 Days After TAVI. (40) 
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A recent study from Zusterzeel et al. from 2018, compared the outcome of the TAVI 
procedure in six premarket clinical trials. In their worked they pooled data from 
premarket TAVR clinical trials comparing short (30 days)- and long-term (2 years) 
outcomes by sex. 
 
The meta-analysis included data from a total of 2515 TAVR patients , 1180 women 
(47%) and 1335 men (53%). 
 In accordance with the findings from the other studies, women had less comorbidity at 
baseline and less prior cardiac procedure, in comparison to men. Conversely their STS 
risk score were higher. The STS risk score includes patient characteristics such as age, 
sex, renal function, cardiac history and current symptoms, diabetes, hypertension, 
echocardiography measures, and other factors that predict the risk of operative mortality 
and morbidity. 
 
The results of the analysis showed  that  “women had a 24% lower mortality risk 
(hazard rate) than men at complete follow-up (female-to-male HR= 0.76 [95% CI: 
0.65–0.89]), while there was no difference at 30 days (OR= 1.00 [0.69–1.46]).”(49) 
The study also registered the risk ischemic stroke  and found that there was not 
difference between sexes at short- and long-term follow-up.  
 
Regarding the incidence  of kidney injury after TAVR, at 30 days, women had a 30% 
lower risk than men, while this difference slightly increased to 33%over the complete 
follow-up period. Major bleedings was more common in women with an increased risk 
of 44%compared to men at 30 days and 22%at long-term follow-up. For the remaining 
time-to-event outcomes, myocardial infarction and device migration, there were no 
differences between the sexes at 30 days or long-term follow-up, but event rates were 
low. (49) 
 
The study states that the increased risk of major bleeding in women after TAVR is due 
to anatomic differences such as smaller body stature and smaller vasculature compared 
to men. 
The hope is that  newer generation TAVR devices are going to mitigate these risks. 
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The study registered an incongruence between the STS risk score and the observed 
mortalities  for both men and women. These findings support the idea that the 
cardiology community needs to develop a TAVR specific risk score for prediction of 
procedural morbidity and mortality. According to the study the late mortality seen in 
women may partly be explained by women having fewer comorbidities and better 
preserved left ventricular function (higher ejection fraction) at baseline.(48) 
 
 
 
Table 8: Kaplan–Meier curves for mortality, ischemic stroke, kidney injury, and 
major bleeding by sex. Curves reflect the probability of the outcome for mortality (top 
left), ischemic stroke (top right), kidney injury (bottom left), and major bleeding 
(bottom right) for women (blue) and men (red). (49) 
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Discussion 
 
In this work the effects of the two existent procedures for the treatment of Aortic 
stenosis have been examined, analysing the different outcomes of the procedures in 
male and female population. 
An extensive research of the existing literature on the topic was carried out, and a 
recollection of the major studies that focused on the possibility of sex-differences in the 
two surgeries. 
 
Sex-differences play a crucial role in the male and female population as early as the  
pathophysiology and the development of aortic stenosis. The differences in the onset of 
the stenosis go on to affect the development of the condition and the body’s response. 
As several studies have shown, the physiological response to the onset of aortic stenosis 
is a left ventricular hypertrophy. Various sex-related factors create a different response 
in male and female subjects.  
 
Women have smaller hearts and therefore a lower stroke volume than men. Women 
exhibit more concentric remodelling and subsequent concentric LV hypertrophy (LVH), 
with higher relative wall thickness and smaller end-diastolic diameter.  Another study 
showed that sex hormones and estrogen receptors and their signalling pathways may 
play a role in sex-specific LV remodelling, modulating growth-factor signalling, 
modulating myocyte necrosis and apoptosis in animal models.(15)  
 
Women also show les fibrosis of the heart when compared to men. As a result of sex-
specific myocardial adaptations to AS, women undergoing TAVR have a smaller LV 
cavity and higher LV ejection fraction (LVEF). 
The post-operative regression of the left ventricle is also affected by sex. Studies show 
that the aforementioned lower incidence of fibrosis, which is linked to plausible 
irreversible non concentric LV remodelling, likely supports regression of concentric 
LVH observed in women after TAVR. (18) 
 
A common finding to all the studies examined are the different baseline characteristics 
for men and women suffering from AS. Female patients present fewer comorbidities but 
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a different risk profile compared with male patients, including older age, frailty, higher 
prevalence of porcelain aorta, moderate to severe mitral regurgitation, lower GFR, and 
higher STS score. (40). Another common finding is the steady constant decline of 
women undergoing SAVR procedure during the years. This is mostly related to the 
arrival of the TAVI procedure which is steadily growing as the best option for older 
patients. 
 From the studies analysed in this work that compare the outcome of SAVR in the two 
sexes, the common findings for all results that compare the outcome of the SAVR 
procedure in men and women is a higher post-operational mortality in women than men.  
The introduction of the TAVI procedure has revolutionised the cardiology approach to 
aortic stenosis. It has confirmed itself as a viable option for the large number of patients 
who were deemed as inoperable for SAVR 
 
Since its introduction various studies have focused on the differences in outcome 
between men and women. The general findings for the studies analysed were that 
women tend to a higher number of post-operative complication in the 30-days after the 
procedure, but have a significant lower long-term mortality. This difference in outcome 
is possibly due to women presenting less moderate/severe aortic insufficiency.  
These results were consistent in he studies that compared the two procedures and for the 
studies that  only analysed the TAVI procedure. The possible reasons for this lower 
mortality after TAVR in women, even though women are usually older and present an 
increased frailty, could be due to there more favourable reverse remodelling, smaller 
annular size or their general longer life expectancy. 
The general aim for these studies was to establish the existence of a sex-related 
advantage in the case of TAVI and disadvantage in the case of SAVR. While further 
studies need to be conducted to effectively determine  the existence of this sex 
advantage for females in the case of TAVI and to further establish the role of the sex-
differences that affect aortic stenosis’s  onset the increasing evidence pointing to a 
concrete advantage for women to undergo the TAVI procedure must be taken into 
account by specialists when consulting with patients and discussed with them.  
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Conclusions 
 
 The aim of this work was to collect and analysed the most important studies regarding 
the sex-difference involved in every step of aortic stenosis and the two available 
procedures for its treatment.  
Aortic stenosis is one of the most common valvular abnormality in the developed world 
and accounts for  closely 40% of patients with native valvular disease with an 
approximately equal prevalence in males and females.(34)  
 
The onset and physiopathology of this condition has been the object of various studies 
and major differences have been registered in the left ventricle hypertrophy, the 
physiological response to aortic stenosis, which turns into heart failure. Women develop 
a concentric hypertrophy while men present  more eccentric pattern. The level of 
fibrosis is lower in women, due to possible genetic and hormonal influences which 
results in a less stiff heart and is a favourable factor for left ventricle regression in the 
post operational recovery. 
 
The study showed that while in the case of SAVR procedure women showed a higher 
mortality than men, this was not the case in the studies that compared TAVI and SAVR 
procedures, where although women showed a higher incidence of 30-day mortality or 
complications the long-term survival rate was higher in the female population. These 
findings were in accordance with the studies that analysed the effect on TAVI procedure 
alone. 
  
While there certainly is a necessity for further studies to analyse and investigate 
thoroughly the various sex-differences that are involved in every aspect of this 
condition, from its effects on the onset to the impact on post-operational mortality, the 
existing evidence should be consulted by specialist when overviewing a patients case 
and the possible advantages for female patient with TAVI procedure should also be 
discussed with patients. 
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